Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Prepaid Assets (2020 - 2025)

Gain Therapeutics has reported Prepaid Assets over the past 6 years, most recently at $1.4 million for Q3 2025.

  • Quarterly results put Prepaid Assets at $1.4 million for Q3 2025, up 713.43% from a year ago — trailing twelve months through Sep 2025 was $1.4 million (up 713.43% YoY), and the annual figure for FY2024 was $159692.0, down 78.47%.
  • Prepaid Assets for Q3 2025 was $1.4 million at Gain Therapeutics, down from $2.3 million in the prior quarter.
  • Over the last five years, Prepaid Assets for GANX hit a ceiling of $2.3 million in Q2 2025 and a floor of $159692.0 in Q4 2024.
  • Median Prepaid Assets over the past 5 years was $664025.0 (2022), compared with a mean of $739148.3.
  • Biggest five-year swings in Prepaid Assets: tumbled 78.47% in 2024 and later surged 741.47% in 2025.
  • Gain Therapeutics' Prepaid Assets stood at $727785.0 in 2021, then tumbled by 71.35% to $208542.0 in 2022, then surged by 255.63% to $741638.0 in 2023, then plummeted by 78.47% to $159692.0 in 2024, then skyrocketed by 800.73% to $1.4 million in 2025.
  • The last three reported values for Prepaid Assets were $1.4 million (Q3 2025), $2.3 million (Q2 2025), and $353252.0 (Q1 2025) per Business Quant data.